Search

Displaying results 4301 - 4310 of 10000 in total
  1. Drug

    Methylene blue

    go.drugbank.com/drugs/DB09241
    ApprovedInvestigational

    Methylene blue is an oxidation-reduction agent. The intravenous form of methylene blue is approved by the FDA for the treatment of pediatric and adult patients with acquired methemoglobinemia. Historically, it has been widely used in Afr...

    Synonyms: Basic Blue 9, C.I. basic blue 9Mixtures: Me NaPhos MB Hyo 1, Uro-MP
  2. Drug

    Galcanezumab

    go.drugbank.com/drugs/DB14042
    ApprovedInvestigational

    A pregnancy exposure registry has been established to evaluate the safety of this drug in pregnant women.[L42060] … Galcanezumab is a humanized monoclonal antibody developed by Eli Lilly and Company against human calcitonin gene-related peptide (CGRP).

    Products: EMGALİTY 120 MG/ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR KALEM, 2 ADET, EMGALİTY 120 MG/ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR KALEM, 3 ADET
  3. Drug

    Anifrolumab

    go.drugbank.com/drugs/DB11976
    ApprovedInvestigational

    Anifrolumab, or MEDI-546, is a type 1 interferon receptor (IFNAR) inhibiting IgG1κ monoclonal antibody indicated in the treatment of adults with moderate to severe systemic lupus erythematosus. … [A237079,L34929] Three monoclonal antibodies (anifrolumab, [rontalizumab], and [sifalimumab]) that target the type 1 interferon pathway entered clinical trials as potential treatments for systemic lupus

    Categories: Type I Interferon Receptor AntagonistProducts: Saphnelo 300 mg/2 mL İnfüzyonluk Çözelti Hazırlamak İçin Konsantre, 1 ADET
  4. Drug

    Taniraleucel

    go.drugbank.com/drugs/DB18311
    Investigational

    Synonyms: The cells are expanded and differentiated in the presence of cytokines including thrombopoietin, SCF, Flt3 ligand, IL-7, IL-15 and IL-2 to generate the NK cell
  5. Drug

    Tacrolimus

    go.drugbank.com/drugs/DB00864
    ApprovedInvestigational

    This FKBP12-FK506 complex inhibits calcineurin which inhibits T-lymphocyte signal transduction and IL-2 transcription. … It reduces peptidyl-prolyl isomerase activity by binding to the immunophilin FKBP-12 (FK506 binding protein) creating a new complex.

    Mixtures: Hyaluronic Acid Sodium Salt 1% / Tacrolimus 0.1% / Urea 20%, Hyaluronic Acid Sodium Salt 1% / Niacinamide 4% / Tacrolimus 0.1%Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
  6. Drug

    Prucalopride

    go.drugbank.com/drugs/DB06480
    ApprovedInvestigational

    Prucalopride is a dihydrobenzofurancarboxamide derivative from the benzofurane family that selectively stimulates 5-HT4 receptors and thus, it presents enterokinetic properties. … [A40254] Prucalopride was developed by Shire Development LLC and approved for use in Europe in 2009,[A40250] in Canada on December 7, 2011 and by the FDA on December 17, 2018.[L4880]

    Categories: Heterocyclic Compounds, 2-Ring, Cytochrome P-450 SubstratesProducts: Resolor Film-coated Tablet 2 mg, RESOLOR ® TABLETAS RECUBIERTAS DE 2 MG
  7. Drug

    Adalimumab

    go.drugbank.com/drugs/DB00051
    ApprovedInvestigational

    A high-concentration, citrate-free formulation of Cyltezo® (adalimumab-adbm), a biosimilar to Humira®, was approved by the FDA in May 2024 for the treatment of multiple chronic inflammatory diseases. … A biosimilar marketed as Hyrimoz, a high-concentration formulation of adalimumab, is also available.[L45643,L45818].

    Products: HUMİRA 20 MG/0,2 ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖR, 2 ADET, HYRİMOZ 40 MG/0,8 ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR KALEM, 2 ADET
  8. Indication

    Thymidine Kinase 2 (TK2 ) Deficiency

    go.drugbank.com/conditions/DBCOND0171486
    Drugs: Doxecitine · Thymidine
    Synonyms: Thymidine Kinase 2 Deficiency, Thymidine Kinase 2 (TK2 ) Deficiency
  9. Indication

    Type 2 Idiopathic Macular Telangiectasia

    go.drugbank.com/conditions/DBCOND0037552
    Drugs: Revakinagene taroretcel
    Synonyms: Type 2 Idiopathic Macular Telangiectasia
  10. Drug

    Sebelipase alfa

    go.drugbank.com/drugs/DB11563
    ApprovedInvestigational

    [L39337] Sebelipase alfa is a recombinant form LAL approved for the treatment of LAL deficiency. … In addition, patients with LAL deficiency typically develop dyslipidemia, which itself contributes to a number of adverse cardiovascular outcomes.

    Products: KANUMA® 2 MG/ML CONCENTRADO PARA SOLUCION PARA INFUSION.